Clinical Trial Update: High Dose BAYA1040 CR: a Long Term Extension Study [Phase 3]

View source ↗

Summary

A long-term extension Phase 3 trial of the high-dose formulation BAYA1040 CR for hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• BAYA1040 CR

Snippet

Sponsor: Bayer | Conditions: Hypertension | Phase 3 | Status: COMPLETED